Atlas Trials

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Clinical trial NCT04523662 · UNKNOWN

Trial details

NCT number
NCT04523662
Sponsor
Beijing Tsinghua Chang Gung Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2020-08-30
Primary completion
2022-08-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.